Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis

被引：2

作者：

Pogosova, Nana ^{[1
]}

Bosch, Jacqueline

Bhatt, Deepak L. ^{[4
]}

Fox, Keith A. A. ^{[5
]}

Connolly, Stuart J. ^{[2
,3
,6
]}

Alings, Marco ^{[7
]}

Verhamme, Peter ^{[8
]}

Muehlhofer, Eva ^{[9
]}

Shestakovska, Olga ^{[2
]}

Yusuf, Salim ^{[2
,3
,6
]}

Eikelboom, John W. ^{[2
,3
,6
]}

机构：

[1] Natl Med Res Ctr Cardiol, Moscow, Russia

[2] Populat Hlth Res Inst, Hamilton, ON, Canada

[3] McMaster Univ, Hamilton, ON, Canada

[4] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA

[5] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland

[6] Hamilton Hlth Sci, Hamilton, ON, Canada

[7] Amphia Ziekenhuis & WCN, Utrecht, Netherlands

[8] Univ Leuven, Leuven, Belgium

[9] Bayer AG, Wuppertal, Germany

来源：

CIRCULATION | 2022年 / 145卷 / 25期

关键词：

aspirin; coronary artery disease; peripheral artery disease; rivaroxaban; venous thromboembolism;

D O I：

10.1161/CIRCULATIONAHA.122.059405

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1875 / 1877

页数：3

共 50 条

[21] Indinavir 800 mg plus ritonavir 200 mg twice-daily as salvage therapy in heavily pretreated patients
Junod, P
Baril, JG
Laplante, F
ANTIVIRAL THERAPY, 2002, 7 (03) : L74 - L75
[22] Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism - A meta-analysis
Couturaud, F
Julian, JA
Kearon, C
THROMBOSIS AND HAEMOSTASIS, 2001, 86 (04) : 980 - 984
[23] The COMPASS Trial Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease
Steffel, Jan
Eikelboom, John W.
Anand, Sonia S.
Shestakovska, Olga
Yusuf, Salim
Fox, Keith A. A.
CIRCULATION, 2020, 142 (01) : 40 - 48
[24] Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
Lee, Mei-Chuan
Liao, Chia-Te
Toh, Han Siong
Chou, Chih-Chen
Chang, Wei-Ting
Chen, Zhih-Cherng
Wu, Wen-Shiann
Yu, Tsung
Strong, Carol
CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (03) : 539 - 547
[25] Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases
Mei-Chuan Lee
Chia-Te Liao
Han Siong Toh
Chih-Chen Chou
Wei-Ting Chang
Zhih-Cherng Chen
Wen-Shiann Wu
Tsung Yu
Carol Strong
Cardiovascular Drugs and Therapy, 2021, 35 : 539 - 547
[26] Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, Timothy P.
Hochhaus, Andreas
Kantarjian, Hagop M.
Cervantes, Francisco
Guilhot, Francois
Niederwieser, Dietger
le Coutre, Philipp D.
Rosti, Gianantonio
Ossenkoppele, Gert
Lobo, Clarisse
Shibayama, Hirohiko
Fan, Xiaolin
Menssen, Hans D.
Kemp, Charisse
Larson, Richard A.
Saglio, Giuseppe
HAEMATOLOGICA, 2014, 99 (07) : 1204 - 1211
[27] Valsartan/Sacubitril Reduces Mortality More Than Enalapril 10 mg Twice Daily in Patients with Heart Failure
Ebell, Mark H.
AMERICAN FAMILY PHYSICIAN, 2015, 91 (07) : 490 - 492
[28] Clinically relevant interpretation of genotype for resistance to ritonavir (100 mg twice daily) plus saquinavir (800 mg twice daily) in HIV-1-infected protease inhibitor-experienced patients
Marcelin, AG
Dalban, C
Peytavin, G
Delaugerre, C
Agher, R
Katlama, C
Costagliola, D
Calvez, V
ANTIVIRAL THERAPY, 2003, 8 (03) : U102 - U103
[29] The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism
Hom, Lindsay
Sobieraj, Diana M.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 198 : 87 - 88
[30] Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention
Eikelboom, John W.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0C) : C8 - C13

← 1 2 3 4 5 →